Search company, investor...

Founded Year



Series E | Alive

Total Raised




Last Raised

$514M | 2 yrs ago

About Medlinker

Medlinker is a China-focused mobile platform that allows physicians to social network and communicate with each other. Doctors on the platform can find contacts of each other and discuss treatment measures for specific cases.

Headquarters Location

Floor 2, Block B6, Tianfu Software Park, No.99 Tianhua First Road

Chengdu, Sichuan, 610041,


(86 28) 83350767



Research containing Medlinker

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Medlinker in 1 CB Insights research brief, most recently on Feb 23, 2022.

Expert Collections containing Medlinker

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Medlinker is included in 3 Expert Collections, including Unicorns- Billion Dollar Startups.


Unicorns- Billion Dollar Startups

1,214 items


Digital Health

10,714 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.



2,856 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Latest Medlinker News

2023's first AI medical conference was held successfully

Nov 2, 2023

News Provided By Share This Article PEKING, CHINA, November 1, 2023 / / -- On October 29, 2023, the first AI Medical Conference 2023 was held in Chengdu. At the conference, Medlinker announced the establishment of the AI Academic Committee. Nobel Prize winner in Physiology or Medicine, German biophysicist Erwin Neher serves as the chief scientist, Chinese Academy of Sciences academician Zhang Xu serves as the academic lead, and expert consultants also include top experts in the fields of endocrinology, gastroenterology, urology, neurology, respiratory medicine, oncology, cardiology, nephrology, and general practice. Members of Medlinker's AI Academic Committee include top experts and scholars in medicine and artificial intelligence. In the future, Medlinker will work closely with experts from the AI Academic Committee on model optimization, training strategies, evaluation testing, etc, of large medical language models to further promote the R&D and transformation of AI medical technology achievements and provide more accurate, reliable and personalized services and support to doctors and patients. At the same time, the Medlinker AI Academic Committee will also pay attention to issues such as ethics and privacy to ensure that the application of AI technology in the medical field complies with social morals, laws, and regulations. Multi-party collaboration builds the core competitiveness of AI medical products. In recent years, the accelerated accumulation of technological capabilities and massive data resources, huge application needs, and an open market environment have combined to form China's unique advantages for the development of artificial intelligence. From the four important links of disease prevention, diagnosis, treatment, and rehabilitation, AI has become an indispensable assistant in the medical field. Academician Zhang Xu said in his speech: "In this era, the development of medical AI has become an important engine for medical progress. Through continuous breakthroughs and applications of medical AI technology, we will be able to provide patients with more efficient, safer, and more convenient medical services, allowing more patients to enjoy the dignity of life. Among the flourishing medical AI products, Medlinker's MedGPT has demonstrated its unique characteristics and charm." Medlinker has been profoundly cultivating digital healthcare for many years and has continued to innovate by combining digital technologies with medicine. In April, it launched MedGPT, the country's first large model-driven AI doctor. As Medlinker founder and CEO Wang Shirui said in his keynote speech: "Medlinker is at the forefront of medical AI. It has also experienced bottlenecks in the process, and the emergence of generative AI has brought changes to various fields, including healthcare. By building a brand new dual-system technical framework and through countless discussions and verifications, the launched MedGPT has performed well in multiple small-scale clinical trials. However, medicine is an industry with an extremely low tolerance for errors. Therefore, Medlinker tirelessly pursues '100%' certainty and accuracy, which needs to be continuously demonstrated and improved through serious means like clinical trials." In November, Medlinker will partner with 6 top 3A hospitals, including West China Hospital of Sichuan University, many secondary hospitals, primary hospitals, and experts from the Medlinker AI Academic Committee to carry out the world's largest AI medical clinical project so far. This clinical project involves multiple disciplines, multiple centers, multiple levels, and over 30,000 research samples, adopts a mixed research design of observational studies and randomized controlled trials, and hopes to fully understand the actual effects and value of MedGPT in medical practice. Wang Shirui revealed in his speech that Medlinker has planned 22 clinical specialties in the future, with dozens of top experts participating and an expected total sample size of over 100,000 in large clinical trials. Medlinker's AI diagnosis and treatment system driven by large models: MedGPT, for the first time, broke through the difficulty that AI could not engage in continuous free dialogue with actual patients, supports multimodal input and output in diagnosis and treatment scenarios, and possesses medical reasoning and decision-making capabilities. This disruptive innovation and creation allows unlimited imagination for the future medical landscape. "MedGPT is like an AI doctor who can 'pass on knowledge and educate people', benefit more grassroots doctors and medical students, improve doctors' diagnostic and treatment efficiency, benefit more patients, and assist experts in academic research." At the meeting, Professor Erwin Neher and authoritative experts shared their visions and clinical explorations of the application of medical AI. Standards come first to promote AI medical innovation and develpment jointly. At present, generative AI is leading a new wave of AI fever, showing immense potential to disrupt and reshape industries. In healthcare, the penetration and development speed of AI technology is equally astonishing. The emergence of foundation models and large language models provides new momentum for the development of medical AI while also bringing new challenges. In the roundtable session, guests discussed "Virtual and Reality: Opportunities and Challenges of Generative AI in Medical Applications" from different perspectives. Regarding the application prospects of generative AI in medical scenarios, guests agreed unanimously that this is beyond doubt. First, generative AI can change the information asymmetry between doctors and patients, allowing patients to obtain more medical information and participate more actively in treatment decisions. Second, generative AI can assist in diagnosis, personalized treatment, drug research and development, intelligent diagnosis and treatment assistants, etc., to improve medical efficiency and diagnostic accuracy. In addition, generative AI can also speed up new drug research and screening, improving the efficiency and success rate of drug development. However, the medical industry is unique. In promoting the development of AI medicine, how to provide product safety and effectiveness, how to ensure data and patient privacy, and how to ensure the controllability of large models need to be seriously researched and solved in the process of promoting AI medicine. It is essential to formulate and implement relevant standards in the medical field. It will improve the safety and effectiveness of medical work, promote the sharing and exchange of medical information, improve the standardization of medical services, and promote innovation and development of the medical industry. Artificial intelligence technology is advancing rapidly, and medicine is entering a brand-new era. This conference provides a platform for top experts and scholars at home and abroad to fully communicate, collide, and explore the field of AI medicine. In the future, it is hoped that more forces will join hands to continuously innovate so that AI technology can provide better support and services to the medical, and better empower doctors to serve patients. Zhou Ying

Medlinker Frequently Asked Questions (FAQ)

  • When was Medlinker founded?

    Medlinker was founded in 2014.

  • Where is Medlinker's headquarters?

    Medlinker's headquarters is located at Floor 2, Block B6, Tianfu Software Park,, Chengdu.

  • What is Medlinker's latest funding round?

    Medlinker's latest funding round is Series E.

  • How much did Medlinker raise?

    Medlinker raised a total of $764.74M.

  • Who are the investors of Medlinker?

    Investors of Medlinker include Sino Biopharmaceutical, HongShan, China Renaissance, China Health Industry Investment Fund, China Capital Zhongcai Fund Management and 7 more.

  • Who are Medlinker's competitors?

    Competitors of Medlinker include We Doctor and 5 more.


Compare Medlinker to Competitors

Gerson Lehrman Group Logo
Gerson Lehrman Group

Gerson Lehrman Group (GLG) focuses on providing expert insights. The company offers services such as connecting clients with experts for phone or video calls, providing quantitative and qualitative research, assembling target populations for surveys, and offering market assessments and competitive analyses. It primarily serves sectors such as business, technology, medical devices and diagnostics, pharmaceuticals and biotechnology, industrials, consumer goods, payments and insurance, finance, and professional services. It was founded in 1998 and is based in New York, New York.

Pathway Logo

Pathway focuses on providing clinicians and patients with efficient access to important medical information. The company offers a medical knowledge platform that provides concise summaries of clinical guidelines, trials, and other relevant information, as well as interactive algorithms for patient-specific guidance. Pathway primarily serves the healthcare industry. It was founded in 2018 and is based in Montreal, Canada.

The Rounds Logo
The Rounds

The Rounds operates a professional network created specifically for Canadian physicians. Its network is used by physicians to collaborate on cases, discuss journals, reconnect with colleagues, and share knowledge. The Rounds was formerly known as Mlkmn. The company was founded in 2012 and is based in Halifax, Canada.

HealWell24 Logo

HealWell24 provides healthcare services. It offers physiotherapy, nursing care, a home intensive care unit (ICU) setup, home dental care, palliative care, and elderly care at home and in hospitals. It also offers post-operative care besides collecting data across various therapeutic areas and working with pharmacies and insurance companies. It was founded in 2017 and is based in Mumbai, India.


Medpeople is a startup focused on providing modern, simple, and flexible solutions for healthcare staffing. The company offers a digital platform where healthcare providers and consultants can post and apply for jobs, manage work history, negotiate salaries, schedule, and follow up, providing a one-stop solution for both employers and consultants. The company primarily serves the healthcare industry. It was founded in 2016 and is based in Stockholm, Sweden.

TheMednet Logo

TheMednet offers a peer-to-peer digital platform helping physicians unlock knowledge. It develops a physician-only community for answers to real-world clinical questions in oncology. Its answers are indexed and searchable so that every physician can access knowledge to provide their patients with the required care. It was founded in 2014 and is based in New York, New York.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.